Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: William Partmann who started this subject	3/23/2004 8:56:59 AM
From: david staton	Read Replies (1) of 10345

Morgan Stanley Overweight - stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months 07:44 ELN Elan Corp resumed with an Overweight at Morgan Stanley (18.40 ) -- Update -- Morgan Stanley resumes coverage on ELN with an Overweight rating and $30 target; firm's investment thesis is that: 1) the co's R&D platform is more valuable than expectations (mainly Antegren), 2) successful restructuring of the balance sheet will result in less financial risk, 3) legal risks will diminish without material harm to the co, and 4) mgmt has the skills to build an integrated pharma/biotech co.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next